Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials

Ulrich Laufs,Christie M Ballantyne,Maciej Banach,Harold Bays,Alberico L Catapano,P Barton Duell,Anne C Goldberg,Antonio M Gotto,Lawrence A Leiter,Kausik K Ray,LeAnne T Bloedon,Diane MacDougall,Yang Zhang,G B John Mancini

Journal of Clinical Lipidology（2022）

引用 15|浏览34

暂无评分

摘要

•Bempedoic acid monotherapy lowered LDL-C in patients not taking a statin by 26.5%•Bempedoic acid + ezetimibe FDC lowered LDL-C in patients not on statins by 39.2%•Bempedoic acid was generally well tolerated in patients unable to take a statin•Muscle-related disorders with bempedoic acid were comparable to placebo

查看译文

关键词

Bempedoic acid,Ezetimibe,Low-density lipoprotein cholesterol,Statin,Statin-associated muscle symptoms (SAMS),Statin intolerance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要